How can we tell if PET imaging for cancer is cost effective?

The Lancet Oncology

Volumn 11, Issue 8, 2010, Pages 711-712

  Manus, Michael P Mac ^a,b   Hicks, Rodney J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; FUNDING; HEALTH CARE PERSONNEL; HODGKIN DISEASE; HUMAN; LAPAROTOMY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MOLECULAR IMAGING; NOTE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; THORACOTOMY;

COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 77955245741     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70164-9     Document Type: Note

References (10)

1. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002, 359:1388-1393.
2. Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 2006, 24:1800-1806.
3. Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009, 151:221-228.
4. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009, 361:32-39.
5. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 2004, 22:2357-2362.
6. Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med 2009, 50:1036-1041.
7. Cheson B The case against heavy PETing. J Clin Oncol 2009, 27:1742-1743.
8. Manus MP Mac, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non small cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001, 92:886-895.
9. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001, 19:111-118.
10. Hillner BE, Siegel BA, Shields AF, et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 2009, 115:410-418.